About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

<table>
<thead>
<tr>
<th>Drug</th>
<th>eluxadoline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brand Name</td>
<td>Viberzi™</td>
</tr>
<tr>
<td>Dosage Form(s)</td>
<td>75 mg and 100 mg</td>
</tr>
<tr>
<td>Manufacturer</td>
<td>Allergan Pharma Co.</td>
</tr>
</tbody>
</table>

**Submission Type**

New Submission

**Use Reviewed**

Irritable bowel syndrome with diarrhea (IBS-D) in adults

**Common Drug Review (CDR)**

Yes, CDR recommended: Do Not Reimburse. Visit the CDR website for more details: [https://cadth.ca/sites/default/files/cdr/complete/SR0560_cdr_complete_Viberzi_Aug_29_18.pdf](https://cadth.ca/sites/default/files/cdr/complete/SR0560_cdr_complete_Viberzi_Aug_29_18.pdf)

**Provincial Review**

Eluxadoline was reviewed internally and was not reviewed by the Drug Benefit Council (DBC) because the CDR recommended not to list eluxadoline for IBS-D.

**Drug Coverage Decision**

Non-Benefit

**Date**

June 11, 2019.

**Reasons**

Eluxadoline was not reviewed by the DBC because it received a “Do not list” recommendation from the CDR. The Ministry of Health (Ministry) reviewed clinical evidence and pharmacoeconomic reports prepared by the CDR, the Final Canadian Drug Expert Committee (CDEC) Recommendation and Reasons, Clinical Practice Reviews from one specialist and one general practitioner. The Ministry did not receive any Patient Input Questionnaire responses from patients, caregivers, or patient groups. The Ministry’s decision is consistent with CDEC’s recommendation.

- In two studies, eluxadoline demonstrated a small advantage over placebo in the primary composite outcome (daily pain response and daily stool consistency response), however, only approximately one third of patients were considered responders. There were no statistically significant differences between eluxadoline and placebo for the percentage of daily pain responders in either study.
- Based on available evidence, more patients discontinued eluxadoline that placebo due to adverse events, there was no clear quality of life improvements, and no data comparing eluxadoline to commonly used treatment options for IBS-D.

**Other Information**

None
The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the Drug Benefit Council (DBC) gives advice to the Ministry. The DBC looks at:
- whether the drug is safe and effective
- advice from a national group called the Common Drug Review (CDR)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:
- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit the The Drug Review Process in B.C. - Overview and Ministry of Health - PharmaCare for more information.

This document is intended for information only.
It does not take the place of advice from a physician or other qualified health care provider.